|Bid||469.00 x 0|
|Ask||470.00 x 0|
|Day's range||460.00 - 470.00|
|52-week range||42.00 - 646.50|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||14 Apr 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||277.00|
Market forces rained on the parade of Silence Therapeutics plc (LON:SLN) shareholders today, when the analysts...
European shares fell today as many investors stayed on the sidelines ahead of a number of key events this week that could have a big impact on financial markets in the months to come. On Wednesday the Federal Reserve meets and on Thursday the UK holds its general election and new ECB chief Lagarde holds her first policy meeting.
There is still plenty of uncertainty surrounding UK politics ahead of Thursday's vote and while that may just be enough to quash any temptation of buying into cheaply valued UK equities, waiting too much could turn out to be the wrong strategy. "Trends can go on longer than you expect but waiting for greater clarity is a dangerous game – when it finally arrives, markets are likely to move very quickly," writes Richard Colwell, head of UK equities at Columbia Threadneedle.
Sure, the polls are giving his Conservative Party a comfortable lead over Labour's Jeremy Corbyn but the point isn't about being brave (or foolish enough) to trust the polls 100%. Nope, it's a bit further than that, say 120%!
Things can always get worse: shares in Tullow Oil opened down less than 50%, quickly crossed that benchmark and hit the -60% bar within an hour of trading. Talking about wild moves on the UK market, The Share Centre has just come up with a list of spectacular moves in 2019.
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
Silence Therapeutics (LON:SLN) is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's8230;
If you own shares in Silence Therapeutics plc (LON:SLN) then it's worth thinking about how it contributes to the...